Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 11;3(1):28–41.e8. doi: 10.1016/j.medj.2021.12.002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Test-negative case-control analysis to compare the odds of symptomatic infection after vaccination with mRNA-1273 versus BNT162b2

(A) The primary analysis was conducted as a test-negative case-control study, with positive symptomatic SARS-CoV-2 PCR tests considered as cases and negative symptomatic tests considered as controls. We compared the odds of symptomatic infection after full vaccination with mRNA-1273 versus after full vaccination with BNT162b2, while adjusting for clinical and demographic covariates.

(B) Odds ratios (ORs) of symptomatic infection obtained in the crude analysis (top) and in the adjusted analysis using conditional logistic regression (CLR) (bottom). In each case, ORs are shown for the entire study duration (December 1, 2020 through September 22, 2021), the early epoch (December 1, 2020 through May 31, 2021), and the late epoch (July 1, 2021 through September 22, 2021). The x axis is log-transformed such that, for example, ORs of 0.5 and 2 are equidistant from the null hypothesis odds ratio of 1. Error bars represent 95% confidence intervals.

(C) Estimated effectiveness of mRNA-1273 and BNT162b2 against symptomatic infection in the early epoch and the late epoch. In each time period, effectiveness estimates were derived by comparing the odds of symptomatic infection after full vaccination versus during the 10 days after the first dose. Error bars represent 95% confidence intervals.